FTC approves final order preserving competition in US markets for animal health products

27 February 2017

Following a public comment period, the US Federal Trade Commission has approved a final order settling charges that Boehringer Ingelheim’s $13.53 billion asset swap with Paris, France-based Sanofi (Euronext: SAN) would likely be anticompetitive.

First announced in December 2016, the FTC’s complaint alleged that, as proposed, the swap would likely harm competition in the US markets for various vaccines for companion animals, or pets, and certain parasite control products for cattle and sheep.

The order requires that family-owned German pharma major Boehringer Ingelheim divest the canine, feline and rabies vaccines identified in the complaint to US firm Eli Lilly (NYSE: LLY) and its Elanco Animal Health division, and the parasite control products to Germany’s Bayer.
The Commission vote approving the final order was 3-0.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK